Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Oligodendrocytes and the early multiple sclerosis lesion.
Patients feeling severely affected by multiple sclerosis: How do patients want to communicate about end-of-life issues?
Tocilizumab, MS, and NMOSD.
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis.
The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis.
Cyclophosphamide for multiple sclerosis.
Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study.
How Natalizumab Binds and Antagonizes α4 Integrins.
Lipoatrophy in patients with multiple sclerosis on glatiramer acetate.
CD46: The 'multitasker' of complement proteins.
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
Information on natalizumab (marketed as Tysabri)
Treatment of facial myokymia in multiple sclerosis with botulinum toxin.
Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions.
Motor impairments at presentation of clinically isolated syndrome suggestive of multiple sclerosis: Characterization of different disease subtypes.
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Genzyme receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) application
A questionnaire for multinational case-control studies of environmental risk factors in multiple sclerosis (EnvIMS-Q).
Chaperone activity of α B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis.
Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation.
Innovation at RUSH
De novo PMP2 mutations in families with type 1 Charcot-Marie-Tooth disease.

Pages